Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

NIH 15INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Small Cell Lung Carcinoma 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × berzosertib × Clear all
NCT03309150 2024-11-29

ATRi Transition Rollover Study

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
1 enrolled 4 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

NCT02157792 2020-04-01

M6620 First in Human Study

EMD Serono

Phase 1 Completed
200 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡